Hyperfractionated/accelerated regimens for the treatment of non-small cell lung cancer: a systematic review of clinical and cost-effectiveness

Wake B, Taylor R, Sandercock S
Record ID 32002000723
English
Authors' objectives:

This review aims to assess the clinical effectiveness and cost-effectiveness of non-conventional radiotherapy regimens i.e. hyperfractionated, accelerated and combined hyperfractionated/accelerated radiotherapy regimens (with or without adjuvant chemotherapy) in comparison to conventional/standard radiotherapy regimens for patients with inoperable non-small cell lung cancer (NSCLC).

Authors' recommendations: Evidence from included trials suggested that there is a statistically significant survival advantage in two regimens (CHART and split-course, hyperfractionated radiotherapy with chemotherapy). These regimens were associated with relatively small increases in adverse events, although data from one trial on split-course, hyperfractionated radiotherapy with chemotherapy was unclear. Those which were statistically significant were short-term only (CHART).
Authors' methods: Systematic review
Details
Project Status: Completed
Year Published: 2002
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England
MeSH Terms
  • Costs and Cost Analysis
  • Lung Neoplasms
  • Radiotherapy
  • Carcinoma, Non-Small-Cell Lung
Contact
Organisation Name: West Midlands Health Technology Assessment Collaboration
Contact Address: Elaena Donald-Lopez, West Midlands Health Technology Assessment Collaboration, Department of Public Health and Epidemiology, University of Birmingham, Edgbaston, Birmingham B15 2TT Tel: +44 121 414 7450; Fax: +44 121 414 7878
Contact Name: louise.a.taylor@bham.ac.uk
Contact Email: louise.a.taylor@bham.ac.uk
Copyright: University of Birmingham
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.